Search

Displaying results 1981 - 1990 of 8967 in total
  1. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

  2. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor

  3. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.

    Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP, -(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
  4. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [L2640] To know more about the individual components of the ergoloid mixture, please visit [DB11275], [DB11274], [DB11273] and [DB13345]. … [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.

    Synonyms: co-dergocrine mesilate, co-dergocrine mesylateCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds with 4 or More Rings
  5. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] … [A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Calcium glucoheptonate

    go.drugbank.com/drugs/DB00326
    ApprovedInvestigational

    Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. … Calcium is also needed for the heart, muscles, and nervous system to work properly.

  7. Drug

    Loxoprofen

    go.drugbank.com/drugs/DB09212
    ApprovedInvestigational

    A transdermal preparation was approved for use in Japan in January 2006. … It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina.

    Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical Use
  8. Drug

    Alanine

    go.drugbank.com/drugs/DB00160
    ApprovedInvestigationalNutraceutical

    It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.

    Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSION
  9. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    It is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding … Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

  10. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.

    Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaSynonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), )M5RU-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETH